Evidence is mounting that improvements in prevention and treatment are having favorable effects on incidence and outcomes.
Recent studies of trends in acute myocardial infarction (AMI) have not included comprehensive information on MI type, diagnostic criteria, and medications. Now, investigators have examined data on 46,086 hospitalizations for AMI and 18,691,131 person-years of follow-up from the Kaiser Permanente Northern California integrated healthcare system between 1999 and 2008. They assessed changes in patient characteristics, medication use, biomarker levels, and outcomes using administrative codes to distinguish between ST-segment-elevation MI (STEMI) and non–ST-segment-elevation MI (NSTEMI).
During the study period, the hospitalization rate declined by 24%, and the proportion of STEMI events fell markedly. By the end of the study, patients were signi…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association